Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Current Assets (2016 - 2026)

Champions Oncology has reported Current Assets over the past 16 years, most recently at $20.2 million for Q1 2026.

  • For Q1 2026, Current Assets rose 2.48% year-over-year to $20.2 million; the TTM value through Jan 2026 reached $20.2 million, up 2.48%, while the annual FY2025 figure was $22.4 million, 63.93% up from the prior year.
  • Current Assets for Q1 2026 was $20.2 million at Champions Oncology, down from $21.3 million in the prior quarter.
  • Over five years, Current Assets peaked at $22.4 million in Q2 2025 and troughed at $13.2 million in Q3 2024.
  • A 5-year average of $17.9 million and a median of $19.5 million in 2023 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: tumbled 35.17% in 2024 and later surged 63.93% in 2025.
  • Year by year, Current Assets stood at $20.6 million in 2022, then crashed by 31.98% to $14.0 million in 2023, then increased by 0.48% to $14.1 million in 2024, then surged by 51.46% to $21.3 million in 2025, then decreased by 5.38% to $20.2 million in 2026.
  • Business Quant data shows Current Assets for CSBR at $20.2 million in Q1 2026, $21.3 million in Q4 2025, and $21.0 million in Q3 2025.